If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
165
results.
Updated on
11/07/2026 [06:57:00]
Absstract of: US20260192043A1
0000 Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.
Absstract of: US20260191433A1
Systems, devices, and methods for detecting, measuring and classifying meals for an individual based on analyte measurements. These results and related information can be presented to the individual to show the individual which meals are causing the most severe analyte response. These results can be organized and categorized based on preselected criteria or previous meals and results so as to organize and present the results in a format with reference to glucose as the monitored analyte. Various embodiments disclosed herein relate to methods, systems, and software applications intended to engage an individual by providing direct and timely feedback regarding the individual's meal-related glycemic response.
Absstract of: US20260191435A1
0000 Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.
Absstract of: US20260192048A1
0000 A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.
Absstract of: US20260191912A1
Methods for transplanting cells or tissues, in particular islets, into a sub-rectus sheath site. Methods for treating diabetes by transplanting islets, particularly hPSC-islets, into a sub-rectus sheath position. The sub-rectus sheath position is a new site for transplantation.
Absstract of: AU2024395288A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Absstract of: US20260191434A1
Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.
Absstract of: AU2026204844A1
The present invention relates to variants of acid-alpha glucosidase and uses thereof. un u n
Absstract of: GB2644972A
Growth-enhancing peptides and fusion polypeptide are provided. The peptides and fusion polypeptides may be used in cell culture, in particular in the production of cultured meat, as replacement or addition to insulin. There is further provided a cell culture medium comprising at least one of the peptides or fusion polypeptides, and a method for growing cells comprising adding at least one of the peptides or polypeptides to the cell culture medium.
Absstract of: EP4772611A1
The present invention relates to a basal medium composition for animal cells. The basal medium composition for animal cells according to the present invention contains a yeast extract, amino acids, an inorganic salt, and a sugar, wherein the amino acids in the composition include cystine and/or cysteine, and glutamine.
Absstract of: US2025169728A1
The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.
Absstract of: US20260182933A1
In accordance with some implementations, a method includes obtaining blood glucose (BG) data indicative of BG levels of an individual. The method includes obtaining a first sleepiness score associated with the individual. The method includes determining, based at least in part on the BG data, that a low blood sugar alert condition is satisfied. The method includes, in response to determining that the low blood sugar alert condition is satisfied, directing an alert subsystem to generate a first alert output based on the first sleepiness score.
Absstract of: US20260184796A1
0000 Aspects of the present disclosure are directed to methods and compositions for facilitating β-cell regeneration by inhibition of the HIF1α-PFKFB3 pathway. Certain aspects describe methods for treatment and prevention of prediabetes and diabetes, including type 2 diabetes. Also disclosed are methods and compositions for enhancing β-cell regeneration.
Absstract of: WO2026143067A1
The present disclosure provides compositions of stem cell-derived pancreatic islet cells engineered for improved engraftment and methods of use thereof for treating a subject having an insulin deficiency.
Absstract of: US20260182869A1
0000 A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's glucose level. The platform implements a short-term prediction model to generate a daily prediction of the patient's glucose level based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's glucose level during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's glucose level and updates a digital twin of the patient's metabolic profile.
Absstract of: WO2026142537A1
Present invention relates to a needle-free glucose measurement system which enable measurement of blood glucose level using concentration value of N2O molecule available in breath air, which comprises an electronic assembly (1.1) which stabilizes the temperature and flow of wavelength-adjustable laser light source (1.2) and controls wavelength, a laser-based sensor (1) which determines concentration values of N2O molecule by measuring the adsorption amount of detector (1.5) wherein beams coming from laser light source (1.2) are adsorbed by N2O molecules in the breath air in the adsorption cell (1.4), and a processor (2) which determine glucose values in the blood using the concentration data coming from laser-based sensor (1).
Absstract of: US20260182870A1
0000 Techniques disclosed herein relate to food analysis and glucose level management. In some examples, the techniques involve determining a consumption of a food item by a user, receiving data indicative of a glucose level of the user, determining an effect of the food item on the glucose level of the user based on a change of the glucose level of the user, and storing the effect of the food item on the glucose level of the user that includes data associated with one or more effects of the food item on the glucose level of the user.
Absstract of: US20260182931A1
0000 The disease management system can determine a measurement of one or more physiological parameters and can determine a disease event based on the one or more measurements. Furthermore, the disease management system can determine a pose of an individual using a pose sensor. Based on an identification of a disease event and a determination that the pose of the individual corresponds to a first pose, the disease management system can cause at least one of an audible, visual, or vibratory alarm. Based on an identification of a disease event and a determination that the pose of the individual does not correspond to the first pose, the disease management system can cause administration of a medication to the individual.
Absstract of: WO2026141211A1
The present invention accurately predicts and notifies the degree of daily discomfort after food intake. The present invention comprises: an acquisition unit that acquires blood glucose-related data related to the blood glucose level of a subject; a prediction unit that, on the basis of the blood glucose-related data, predicts the degree of daily discomfort after a prescribed amount of time from food intake by the subject; and an output unit that outputs the result of prediction by the prediction unit.
Absstract of: US20260188443A1
0000 A method of providing personalized treatment for a diabetes patient including a remote device which is configured to receive a first data indicative of an analyte level of a subject during a first time period, retrieve a first glycated hemoglobin level for the subject associated with the first time period, calculate a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level, compare the calculated first personal apparent glycation ratio to a representative apparent glycation ratio, generate a recommendation based on the comparison, and display a graphical interface comprising the calculated first personal apparent glycation ratio, the representative apparent glycation ratio, and the comparison.
Absstract of: WO2026142802A1
Certain aspects of the present disclosure provide a therapy management system configured to monitor at least glucose concentration levels of a patient during a first time period using one or more glucose sensors to obtain glucose data, and determine a diabetic state classification of the patient based on the glucose data. The diabetic state classification indicates a diabetic state of the patient and comprises one of: a healthy classification, a pre-diabetic classification, a mild type 2 diabetes (T2D) classification, a severe T2D classification, or a gestational diabetes classification. The therapy management system is further configured to provide personalized feedback to the patient based on the determined diabetic state classification, wherein the personalized feedback comprises a recommendation for at least one of an exercise session, a dietary change, a lifestyle modification, a medication adjustment, or a continuous glucose monitoring wear schedule.
Absstract of: WO2026142762A1
In an embodiment, a system for mitigating diabetic ketoacidosis (DKA) risk for a patient in real-time includes a continuous glucose monitoring (CGM) system configured to generate one or more glucose measurements associated with a cunent glucose level of a patient over a period, one or more memories including executable instructions, and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive glucose measurements for the patient from the CGM system, receive insulin data for the patient, evaluate criteria associated with DKA using first information related to the glucose measurements and second information related to the insulin data, detect a risk of DKA for the patient responsive to a combination of the first information and the second information satisfying the criteria associated with DKA, and alert the patient based on the detected risk.
Absstract of: US20260183483A1
0000 A system for managing a patient's glucose level includes a glucose sensor to generate and store data signals for measurements of the patient's glucose level made by the glucose sensor; an insulin pump; and sensor electronics operatively coupled to the glucose sensor, the sensor electronics comprising a memory storing one or more predetermined characteristics associated with the sensor electronics; and a computing device in electronic communication with the sensor electronics. The computing device comprises a processor configured to operate the sensor electronics to (i) receive the generated data signals, (ii) obtain the one or more predetermined sensor characteristics from the memory and (iii) execute a closed-loop algorithm to provide insulin delivery instructions to an insulin pump by at least using the data signals and predetermined characteristics.
Absstract of: AU2024389410A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Nº publicación: US20260182845A1 02/07/2026
Applicant:
ACCURATE MEDITECH INC [TW]
Accurate Meditech Inc.
Absstract of: US20260182845A1
0000 A wearable device for measuring blood glucose and blood pressure for a user includes a main body including a first side and a second side formed on the opposite side of the first side; a first supporting frame protruding from the first side and a second supporting frame protruding from the second side; a belt portion having a first belt end detachably coupled to the first supporting frame, a second belt end detachably coupled to the second supporting frame, and at least one aligning mark, wherein the belt portion is positioned around a wrist of the user; wherein the main body includes at least one pressure sensor array assembly overlaid on a radial artery of the user; wherein the pressure sensor array assembly includes a plurality of apertures arranged one after another to form a cross-shaped pattern and at least four sensor elements arranged in a symmetrical configuration.
BOPI
Electronic site
